| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $15.00B | +12.4% |
| Gross profit | $10.78B | — |
| Operating income | $3.99B | — |
| Net income | $0.69B | -46.0% |
| Gross margin | 71.9% | Net margin 4.6% |
| Revenue Q/Q | -9.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| HUMIRA | $0.69B | 4.6% |
| Botox Cosmetic | $0.67B | 4.5% |
| Imbruvica | $0.56B | 3.7% |
| MAVYRET | $0.35B | 2.3% |
| Ubrelvy | $0.34B | 2.3% |
| Qulipta | $0.30B | 2.0% |
| Other Aesthetics | $0.29B | 1.9% |
| Linzess Constella | $0.28B | 1.9% |
| Juvederm Collection | $0.23B | 1.5% |
| Vyalev | $0.20B | 1.3% |
| Elahere | $0.20B | 1.3% |
| Other Neuroscience | $0.12B | 0.8% |
| Epkinly | $0.08B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $4.22B | 28.1% |
| SG&A | $3.58B | 23.9% |
| Tax & other | $3.29B | 22.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ACN ・ ADBE ・ AMD ・ AES ・ AFL ・ A ・ APD ・ ABNB ・ AKAM ・ ALB ・ ARE ・ ALGN
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies